HCG Q1 results: Cancer care major posts 190% jump in adjusted profit, revenue rises 13%

Kolkata/IBNS: Healthcare Global Enterprises Limited (HCG), India’s largest dedicated cancer private hospital network, under the brand “HCG”, has recently announced its financial results for the quarter ended June 30, 2026.

IBNS • 14 Aug 2026, 11:00 am

Q1 FY27 Results Summary

The company reported strong year-on-year growth in Q1 FY27, with revenue from operations rising 13% to ₹695.1 crore, compared with ₹613.2 crore in Q1 FY26.

Adjusted EBITDA: ₹133.9 crore, up 20% YoY from ₹111.8 crore.
EBITDA margin: Improved to 19.4% from 18.2%, a 121-basis-point increase.
Adjusted PAT: ₹13.8 crore, nearly tripling 190% YoY from ₹4.7 crore.
Sequentially: Revenue increased 7% from Q4 FY26, while adjusted EBITDA rose 7%.

However, adjusted PAT fell 59.6% QoQ from ₹34.1 crore in Q4 FY26, with the PAT margin declining to 2% from 5.2%.

Dr. B. S. Ajaikumar, Founder and Non-Executive Chairman, HealthCare Global Enterprises Ltd., said, "The strong start to FY27 reflects the resilience of HCG's integrated oncology model and our unwavering commitment to clinical excellence. Over the years, we have consistently invested in expanding access to advanced cancer care while building an institution that combines cutting-edge technology, world-class medical expertise, and compassionate patient care.

"As we continue to strengthen our network through strategic capacity expansion and focused investments in innovation, we remain committed to shaping the future of oncology and delivering sustainable long-term value for our patients, clinicians, shareholders, and the communities we serve."

Commenting on the results, Dr. Manish Mattoo, Executive Director & CEO, HealthCare Global Enterprises Limited (HCG), said, "We have started FY27 on a strong note, with revenue growing 13% year-on-year to ₹6,951 million. Excluding North Bangalore hospital, 16 of our 25 centres recorded their highest-ever quarterly revenues, reflecting broad-based growth across our network and sustained demand for our oncology services.

Our focus on increasing the share of high-complexity oncology care and non-institutional business continues to strengthen the quality of our revenue.

Non-institutional revenue grew 17% year-on-year, with its contribution increasing from 67% to 69%, while Adjusted EBITDA grew 20% to ₹1,339 million, with margins improving to 19.4%.